VTYX
vs
S&P 500
VTYX
S&P 500
Over the past 12 months, VTYX has significantly outperformed S&P 500, delivering a return of +237% compared to the S&P 500's +16% growth.
Stocks Performance
VTYX vs S&P 500
Performance Gap
VTYX vs S&P 500
Performance By Year
VTYX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Ventyx Biosciences Inc
Glance View
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. The company is headquartered in Encinitas, California and currently employs 27 full-time employees. The company went IPO on 2021-10-21. The firm is engaged in developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet medical need. Its pipeline includes VTX958, VTX002, VTX2735 and Preclinical NLRP3 Inhibitor Portfolio. The Company’s lead product candidate is VTX958, an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor to address a range of immune-mediated diseases, such as psoriasis, inflammatory bowel disease (IBD), psoriatic arthritis and lupus. The company is developing VTX002, an oral, selective sphingosine 1 phosphate receptor 1 (S1P1R) modulator for ulcerative colitis (UC). The firm is also developing a NOD-like receptor protein 3 (NLRP3) inhibitors to address multiple indications driven by NLRP3 inflammasome activation. Its NLRP3 inhibitor and VTX2735 designed to treat systemic inflammatory diseases such as cardiovascular, hepatic, renal, and rheumatologic diseases.
